10-K: Corcept Therapeutics Reports Record Revenue in 2024, Submits NDA for Relacorilant

Corcept Therapeutics achieved record revenue in 2024 and submitted a New Drug Application (NDA) to the FDA for relacorilant, a potential treatment for hypercortisolism.

Summary

• Corcept Therapeutics is a commercial-stage company focused on developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders.
• In 2024, the company achieved record net product revenue of $675.0 million, compared to $482.4 million in 2023 and $401.9 million in 2022.
• The increase in revenue was primarily driven by higher sales volume and a price increase effective January 1, 2024.
• The company submitted an NDA to the FDA for relacorilant, a proprietary cortisol modulator, as a treatment for patients with hypercortisolism.
• Research and development expenses increased to $246.9 million in 2024, compared to $184.4 million in 2023, due to increased spending on clinical trials and employee compensation.
• Selling, general, and administrative expenses also increased to $280.3 million in 2024, compared to $184.3 million in 2023, primarily due to increased employee compensation and sales and marketing activities.
• The company had cash, cash equivalents, and marketable securities of $603.2 million as of December 31, 2024.
• Corcept expects research and development and selling, general, and administrative expenses to be higher in 2025.
• The company is involved in ongoing patent litigation with Teva Pharmaceuticals regarding generic versions of Korlym.
• The company is also subject to healthcare regulation and enforcement by the federal government and the states where it conducts business.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with record revenue and a new drug application submission, but also acknowledges risks related to competition, litigation, and regulatory changes.

Positives

• Record net product revenue of $675.0 million in 2024 indicates strong commercial performance.
• Submission of NDA for relacorilant represents a significant milestone in the development of a new treatment option for hypercortisolism.
• Positive results from the CATALYST, GRACE and GRADIENT trials support the efficacy and safety of Korlym and relacorilant.
• Strong cash position of $603.2 million provides financial flexibility for future growth and development activities.
• Orphan drug designation for relacorilant in the United States and Europe provides tax credits, reduced regulatory fees, and potential marketing exclusivity.
• The company has a robust portfolio of proprietary selective cortisol modulators.

Negatives

• Increased research and development and selling, general, and administrative expenses may impact profitability.
• Ongoing patent litigation with Teva Pharmaceuticals creates uncertainty and potential financial risk.
• The Inflation Reduction Act of 2022 may limit future revenue from Medicare patients.
• The DAZALS trial did not meet its primary endpoint.

Risks

• Failure to generate sufficient revenue from the sale of our Products would harm our financial results and would likely cause our stock price to decline.
• The availability of generic versions of Korlym could adversely affect our business, results of operations and financial position.
• Public perception of mifepristone or legislation limiting or barring its distribution or use for termination of early pregnancy may limit our ability to sell our Products.
• New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible for us to obtain acceptable prices or adequate insurance coverage and reimbursement for our Products, which would adversely affect our results of operations and financial position.
• Vendors perform many of the activities necessary to carry out our clinical trials, including drug product distribution, trial management and oversight and data collection and analysis. Failure of these vendors to perform their duties or meet expected timelines may prevent or delay approval of our product candidates.
• Our efforts to discover, develop and commercialize our product candidates may not succeed. Clinical drug development is lengthy, expensive and often unsuccessful. Results of early studies and trials are often not predictive of later trial results. Failure can occur at any time. Even if we deem that our product candidates clinical trial results demonstrate safety and efficacy, regulatory authorities may not agree. Failure to obtain or maintain regulatory approvals for our product candidates would prevent us from commercializing them.
• We may not be able to secure, maintain or effectively assert patent protection for the composition, manufacture, or methods of use of our proprietary, selective cortisol modulators and for the use of our Products to treat hypercortisolism. Litigation is slow and expensive and its outcome is uncertain and subject to challenge on appeal.
• The price of our common stock fluctuates widely and is likely to continue to do so. Opportunities for investors to sell shares may be limited.
• Our stock price may decline if our performance does not meet the guidance we have provided to the public, estimates published by research analysts or other investor expectations.
• We rely on information technology to conduct our business. A breakdown or breach of our information technology systems or our failure to protect confidential information concerning our business, patients or employees could interrupt the operation of our business and subject us to liability.

Future Outlook

Corcept expects research and development and selling, general, and administrative expenses to be higher in 2025.

Industry Context

The announcement highlights Corcept's efforts to compete with established treatments for hypercortisolism, including Signifor, Isturisa, and Recorlev, as well as generic options. The company is also exploring the potential of cortisol modulation in oncology and other therapeutic areas.

Comparison to Industry Standards

• Signifor (pasireotide) Injection, marketed by Recordati S.p.A., is a somatostatin analogue approved for adult patients with Cushings disease.
• Isturisa (osilodrostat) tablets, also marketed by Recordati S.p.A., is another cortisol synthesis inhibitor approved for patients with Cushings disease.
• Recorlev (levoketoconazole), sold by Xeris Biopharma Holdings, Inc., is a chiral form of ketoconazole used to treat patients with hypercortisolism.
• The company's relacorilant is being developed to address the side effects associated with existing treatments, such as hypokalemia and QT interval prolongation.

Legal Proceedings

• The company is involved in ongoing patent litigation with Teva Pharmaceuticals regarding generic versions of Korlym.
• Teva filed a complaint in the Northern District of California, captioned Teva Pharmaceuticals USA, Inc. v. Corcept Therapeutics, Inc., et al. (N.D. Cal.), Case No. 3:24-cv-03567-BLF (the Teva Antitrust Litigation).
• Several named plaintiffs filed a complaint against Corcept in the Alameda County Superior Court for the State of California, captioned, Aetna Inc., Health Care Service Corporation, Humana Inc. and Molina Healthcare Inc. vs. Corcept Therapeutics, Inc ., Case No. 25CV110493.
• Shareholder derivative complaints have been filed in the United States District Court for the District of Delaware by Lauren Williams, captioned Lauren Williams v. G. Leonard Baker, et al. , Civil Action No. 1:19-cv-01830 and Jeweltex Pension Plan, captioned Jeweltex Pension Plan v. James N. Wilson, et al. , Civil Action No. 1:19-cv-02308.
• A shareholder derivative complaint was filed in the Delaware Court of Chancery by Joel B. Ritchie, captioned Joel B. Ritchie v. G. Leonard Baker, et al. , Case No. 2022-0102-SG.
• The company received a records subpoena from the United States Attorneys Office for the District of New Jersey (the NJ USAO) pursuant to Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) seeking information relating to the sale and promotion of Korlym, our relationships with and payments to health care professionals who can prescribe or recommend Korlym and prior authorizations and reimbursement for Korlym.

Stakeholder Impact

• Shareholders: The company's financial performance and development activities may impact shareholder value.
• Employees: The company's growth and expansion may create new employment opportunities.
• Patients: The development of new treatments for hypercortisolism and other disorders may improve patient outcomes.
• Customers: The availability of generic versions of Korlym may impact pricing and access to treatment.
• Suppliers: The company's manufacturing agreements may provide revenue opportunities for suppliers.

Next Steps

• Continue to advance the development of relacorilant and other product candidates.
• Pursue regulatory approval for relacorilant in the United States and other markets.
• Continue to monitor and manage the ongoing patent litigation with Teva Pharmaceuticals.
• Assess overall survival in March 2025 pursuant to the DAZALS study protocol.

Key Dates